Steroid-sparing strategies for managing ICI-induced arthritis: safety and oncological outcomes.
G. De Marchi, Silvia Guella, Donatella Iacono, Marianna Macerelli et autres
it (code pays fourni par la source)
0 citations
PubMed
Marianna Macerelli
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
71Publications signalées
1538Citations signalées
4Affiliations récentes
Les institutions déclarées
Les domaines associés
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research StudiesColorectal Cancer Treatments and Studies
Les publications récentes
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella et autres
it, us, gb, ie, pl, de, gr, fr, es, be, nl, jo, jp, se (code pays fourni par la source)
1 citation
Lung Cancer
P05.16.B DEFINING THE OPTIMAL MGMT METHYLATION CUTOFF AND ITS CORRELATION WITH SIGNIFICANT GENETIC ALTERATIONS
Luca De Marchi, Giacomo Pelizzari, Francesco Tuniz, Marianna Macerelli et autres
it (code pays fourni par la source)
0 citations
Neuro-Oncology
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Maria Lucia Reale, Daniela Scattolin, Antonio Vitale, Francesco Passiglia et autres
it, us (code pays fourni par la source)
4 citations
Lung Cancer
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo et autres
it, gb, us, ie, br, de, ch, pl, gr, fr, es, be, nl (code pays fourni par la source)
2 citations
Journal for ImmunoTherapy of Cancer
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo et autres
it, gb, us, ie, br, pl, de, ch, gr, fr, es, be, nl, jo (code pays fourni par la source)
28 citations
Journal for ImmunoTherapy of Cancer
Antibody–Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives
Carol Zanchetta, Lorenzo De Marchi, Marianna Macerelli, Giacomo Pelizzari et autres
it, nl (code pays fourni par la source)
12 citations
International Journal of Molecular Sciences
The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era
Alexandro Membrino, Carol Zanchetta, Simona Rizzato, Francesco Cortiula et autres
it, nl (code pays fourni par la source)
12 citations
International Journal of Molecular Sciences
1251P Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial
E. Olmetto, Camilla Ciolli Mattioli, Saverio Caini, Marco Del Riccio et autres
it (code pays fourni par la source)
0 citations
Annals of Oncology
AB0216 IMMUNE-RELATED ARTHRITIS: IMPACT OF DMARDs
G. De Marchi, S. Guella, Daniela Iacono, Marianna Macerelli et autres
it (code pays fourni par la source)
0 citations
Annals of the Rheumatic Diseases
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
Giulia Pasello, M. Lorenzi, Daniela Scattolin, Alessandro Del Conte et autres
it (code pays fourni par la source)
6 citations
The Oncologist
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
Brigida Anna Maiorano, Massimo Di Maïo, Linda Cerbone, Evaristo Maiello et autres
it (code pays fourni par la source)
48 citations
JAMA Network Open
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.